| Exclusion Criteria: | 1) Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site and/or agents for AstraZeneca)
2) Previous administration of treatment in the present study
3) Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product (to CTCAE Grade 1 or baseline, except alopecia)
4) Administration of LDAC is clinically contraindicated
5) Patients with AML of French-American-British (FAB) M3 classification Acute Promyelocytic Leukaemia (APL)
6) Patients with blast crisis of chronic myeloid leukaemia
7) QTc interval >/= 470 ms, from a single ECG reading or a mean of three ECG readings, using Fridericia's or Bazzett's correction
8) Any chemotherapy e.g. for prior MDS, or radiotherapy, within 14 days prior to starting the study (not including palliative radiotherapy at local sites)
9) Persistent, chronic, clinically significant toxicities, from any prior anti-cancer therapy greater than CTCAE Grade 1 (except alopecia)
10) Patients with symptomatic clinically defined central nervous system (CNS) disease (asymptomatic patients are eligible if symptom free for > 10 days)
11) Uncontrolled intercurrent illness including, but not limited to, uncontrolled active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations which would limit compliance with protocol requirements
12) Major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that involved general anaesthesia or respiratory assistance
13) Patients with documented cases of human immunodeficiency virus (HIV) or hepatitis B or C
14) Female patients who are breast feeding, or patients of reproductive potential not employing an effective method of birth control
15) History of hypersensitivity to active or inactive excipients of any study medication (AZD1152 or LDAC)
16) Exclusion from this genetic research may be for any of the exclusion criteria specified in the main study or any of the following: Previous allogenic bone marrow transplant; Blood transfusion in the last 120 days of genetic sample collection which was not leukocyte depleted |